From November 1 Spin-Off to Year-End

Sales of 28.6 Billion Won and Operating Profit of 2.7 Billion Won

Samyang Biopharm announced that it held its 1st regular shareholders' meeting on March 23 at Samyang Hall on the basement 1st floor of the Samyang Discovery Center in Pangyo, Seongnam, Gyeonggi Province.


At the shareholders' meeting, all four agenda items were approved as originally proposed: approval of the 1st term financial statements, partial amendment of the articles of incorporation, appointment of an outside director as an audit committee member, and approval of the directors' remuneration limit.

Samyang Biopharm held its first regular shareholders' meeting on the 23rd at Samyang Hall, Basement 1, Samyang Discovery Center in Pangyo. Samyang Biopharm

Samyang Biopharm held its first regular shareholders' meeting on the 23rd at Samyang Hall, Basement 1, Samyang Discovery Center in Pangyo. Samyang Biopharm

View original image

Samyang Biopharm reported sales of 28.6 billion won and operating profit of 2.7 billion won for the period from the date of the spin-off, November 1 last year, to the end of the year.


In his welcoming remarks, CEO Kim Kyungjin said, "Samyang Biopharm has enhanced its portfolio by focusing on medical devices, pharmaceuticals, and new drug development, and has improved profitability through proactive global market expansion. This year, with an even bolder spirit of challenge, we will continue to create opportunities for sustainable growth and innovation."


He further stated, "We aim to become a healthcare solution partner that enhances the quality of human life by diversifying our medical device business portfolio, accelerating our entry into the aesthetic medical field, advancing and developing new technologies for our gene therapy drug delivery platform 'SENS,' driving new drug development, expanding anticancer drug sales, and broadening our mid- to long-term pharmaceutical portfolio."



Meanwhile, Samyang Biopharm has been operating under the leadership of CEO Kim Kyungjin since it was spun off from Samyang Holdings, the holding company of Samyang Group, on November 1 last year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing